Aurinia Pharmaceuticals Inc. (AUPH)

NASDAQ: AUPH · IEX Real-Time Price · USD

5.04

-0.06 (-1.18%)

At close: Apr 15, 2024, 4:00 PM

5.16

+0.12 (2.38%)

After-hours: Apr 15, 2024, 7:28 PM EDT

Aurinia Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Net Income	-78.02	-108.18	-180.97	-102.68	-88.39	-53.08	-70.79	-23.3	-18.61	-19.42	Upgrade
Depreciation & Amortization	11.65	2.71	2.76	1.37	1.17	1.31	1.46	1.48	1.56	1.52	Upgrade
Share-Based Compensation	45.31	32.3	31.24	17.45	7.41	6.86	4.24	1.38	3.22	2.19	Upgrade
Other Operating Activities	-12.4	-6.36	-10.73	14	16.22	-6.71	23.93	1.72	-3.94	-1.19	Upgrade
Operating Cash Flow	-33.46	-79.53	-157.69	-69.86	-63.59	-51.61	-41.17	-18.71	-17.77	-16.91	Upgrade
Capital Expenditures	-0.72	-0.29	-1.5	-7.34	-0.1	-0.07	-0.03	-0.01	-0.05	-0.09	Upgrade
Change in Investments	5.88	-59.68	-84.53	-150.84	7.88	0.01	-7.98	10	0.03	-9.99	Upgrade
Other Investing Activities	-11.86	-0.66	-17.84	-	-	-	-	-	-	-	Upgrade
Investing Cash Flow	-6.71	-60.63	-103.87	-158.19	7.78	-0.07	-8	9.99	-0.02	-10.08	Upgrade
Share Issuance / Repurchase	4.9	2.43	221.11	194.38	243.85	4.01	166.47	42.62	0.84	49.49	Upgrade
Debt Issued / Paid	-10.03	0	0	0	0	0	0	0	0	-1.6	Upgrade
Other Financing Activities	-	-	-	-	-	-	8.68	-	-	-	Upgrade
Financing Cash Flow	-5.13	2.43	221.11	194.38	243.85	4.01	175.15	42.62	0.84	47.89	Upgrade
Exchange Rate Effect	0	0	0	0	0	0	0	0	0	-0.02	Upgrade
Net Cash Flow	-45.3	-137.73	-40.45	-33.67	188.05	-47.66	125.98	33.89	-16.95	20.89	Upgrade
Free Cash Flow	-34.18	-79.82	-159.19	-77.2	-63.69	-51.69	-41.19	-18.72	-17.82	-16.99	Upgrade
Free Cash Flow Margin	-19.47%	-59.55%	-349.07%	-154.04%	-20027.04%	-11163.07%	-9855.02%	-10820.23%	-7581.28%	-6112.95%	Upgrade
Free Cash Flow Per Share	-0.24	-0.56	-1.23	-0.65	-0.69	-0.61	-0.49	-0.48	-0.56	-0.54	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).